Galza-Met (Vildagliptin+Metformin HCI) tablets are manufactured by CCL pharmaceuticals (PVT.) Ltd.
It combines with different mechanism of action to improve glycaemic control in patients with type two diabetes.
It decreases hepatic glucose production, decreases intestinal absorption of glucose, improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Each pack contains:
Each pack contains 14 tablets of 50/1000mg.
Galza-Met 50/100 tablet
Each film coated tablet contains:
Vildagliptin (manufacturer’s specs.) 50mg
Metformin HCIBP 500mg
(CCL Pharmaceuticals specifications)
This medicine is showed as a change to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus whose diabetes is not adequately controlled on metformin hydrochloride.
Or vildagliptin alone or who are already treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.
As directed by physicain.
Do not exceed the maximum daily dose of vildagliptin(100mg). The recommended starting dose should be based on the patient’s current regimen of vildagliptin and/or metformin hydrochloride.
Galza-met is not a substitution for insulin in insulin-requiring patients. It should not be used in patients with type 1 diabetes or to treat diabetic ketoacidosis. It is also not recommended in patients with hepatic impairment.
Store below 30 degrees Celsius.
Protect from heat, sunlight and moisture.
Keep out of the reach of children.
To be sold on the prescription of registered medical practitioner only.
Note: For details information see package insert.
You can also contact the manufacture of this medicine at https://cclpharma.com
You can buy online at https://dvago.pk
By: Javairia Israr.